Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
AMES, Iowa, Feb. 16, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and year end 2017 financial results on Thursday, March 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on clinical and business development activities.
NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.
Access to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/8rng5oig. A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 9466627.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod, the company’s leading IDO inhibitor, is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com, and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
(515) 598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
